Private Eye

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Three buying at ProMIS Neurosciences (T:PMN)

Updated Thursday Jan 24, 2019 01:36 AM EDT

Anthony Giovinazzo, a Director, acquired 325,000 Common Shares on a direct ownership basis at a price of $0.230 through a prospectus or prospectus exempt offering on January 22nd, 2019. The insider also acquired 325,000 Warrants with an exercise price of $0.480 for five long years. This represents a $74,750 investment into the company's shares and an account share holdings change of 38.2%.

Elliot Paul Goldstein, CEO and Director, acquired 115,607 Common Shares and 115,607 Warrants on a direct ownership basis. This represents a $26,590 investment into the company's shares and an account share holdings change of 1.6%.

Eugene Warren Williams, a Director, acquired 115,607 Common Shares and 115,607 Warrants on a direct ownership basis. This represents a $26,590 investment into the company's shares and an account share holdings change of 1.5%.

ProMIS Neurosciences is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
N/A
N/A
N/A
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to ProMIS Neurosciences Inc. (PMN)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

No Comments

Twitter

Search (past week) for $PMN.CA

  • No tweets found

Stocktwits